Explore more about: COVID-19

The federal government has expanded the Home Test to Treat program, an entirely virtual community health program that offers free COVID-19 health services.

Some people using antigen tests have experienced a negative test result only to find out that they have the virus. New research shows that repeat testing every other day increases the detection of the SARS-CoV-2 virus.

New recommendations from the NIH Rapid Acceleration of Diagnostics (RADx®) Tech Program provide a blueprint for the design and manufacture of more accessible diagnostic tests.

One day, the ultrasound equipment that health care professionals use for essential diagnostic imaging may no longer be confined to the clinic, instead operated by patients in the comfort of their homes. New research marks a major step toward that future.

NIH has launched the Home Test to Treat program, an entirely virtual community health intervention that will provide free COVID-19 health services—at-home rapid tests, telehealth sessions and at-home treatments—in selected communities.

Reporting a positive or negative test result just became easier through a new website from the National Institutes of Health. MakeMyTestCount.org, developed through NIH’s Rapid Acceleration of Diagnostics (RADx®) Tech program, allows users to anonymously report the results of any brand of at-home COVID-19 test.

NIH announced it will provide funding to diagnostic test manufacturers for the development of the next generation of COVID-19 tests, with a focus on improved accessibility. Source: LabPulse 

The use of rapid Covid tests has soared this year with the spread of omicron and free shipments organized by the Biden Administration. But in August the US Food and Drug Administration cautioned that people who get a negative result should still repeat the test a couple days later. That communication has led to a lot of confusion. Source: Bloomberg

A research team funded by the National Institutes of Health has shown that commercially available rapid antigen tests can detect past and present variants of concern and has identified potential mutations that may impact test performance in the future.

NIH has issued two new funding opportunities for diagnostic test manufacturers to develop the next generation of COVID-19 diagnostics.